128 related articles for article (PubMed ID: 32888192)
1. Continuous intravenous infusion of enoxaparin controls thrombin formation more than standard subcutaneous administration in critically ill patients. A sub-study of the ENOKSI thromboprophylaxis RCT.
Vahtera A; Szanto T; Lassila R; Valkonen M; Sivula M; Huhtala H; Pettilä V; Kuitunen A
Acta Anaesthesiol Scand; 2021 Jan; 65(1):109-115. PubMed ID: 32888192
[TBL] [Abstract][Full Text] [Related]
2. Plasma anti-FXa concentration after continuous intravenous infusion and subcutaneous dosing of enoxaparin for thromboprophylaxis in critically ill patients. A randomized clinical trial.
Vahtera A; Valkonen M; Huhtala H; Pettilä V; Kuitunen A
Thromb Res; 2017 Oct; 158():71-75. PubMed ID: 28846877
[TBL] [Abstract][Full Text] [Related]
3. Bioactivity of enoxaparin in critically ill patients with normal renal function.
Gouya G; Palkovits S; Kapiotis S; Madl C; Locker G; Stella A; Wolzt M; Heinz G
Br J Clin Pharmacol; 2012 Nov; 74(5):806-14. PubMed ID: 23227470
[TBL] [Abstract][Full Text] [Related]
4. Anti-factor X activity levels with continuous intravenous infusion and subcutaneous administration of enoxaparin after coronary artery bypass grafting: A randomized clinical trial.
Parviainen MK; Vahtera A; Ånäs N; Tähtinen J; Huhtala H; Kuitunen A; Järvelä K
Acta Anaesthesiol Scand; 2022 Oct; 66(9):1083-1090. PubMed ID: 35908159
[TBL] [Abstract][Full Text] [Related]
5. The study of the thrombin generation mechanism and the effect of low molecular weight heparin as thromboprophylaxis in patients undergoing total knee and hip replacement.
Gionis MN; Ioannou CV; Katsamouris AN; Katonis P; Balalis K; Sfyridaki K; Elalamy I; Gerotziafas GT
Thromb Res; 2013; 132(6):685-91. PubMed ID: 24182549
[TBL] [Abstract][Full Text] [Related]
6. Low molecular weight heparin for venous thromboembolism prophylaxis in general Intensive Care Unit patients: an anti-factor Xa level-based approach.
Zohar N; Ellis MH; Dichtwald S; Meyer A; Zohar E; Ifrach N
Minerva Anestesiol; 2023 May; 89(5):425-433. PubMed ID: 36326777
[TBL] [Abstract][Full Text] [Related]
7. The Effectiveness of the Intermediate and Therapeutic Doses of Enoxaparin in COVID-19 Patients: A Comparative Study of Factor Xa Inhibition.
Masjedi M; Azadikhah S; Zand F; Asmarian N; Sabetian G; Ostovan M; Naderi-Boldaji V
Acta Haematol; 2023; 146(2):137-143. PubMed ID: 36538914
[TBL] [Abstract][Full Text] [Related]
8. Results of rotational thromboelastometry, coagulation activation markers and thrombin generation assays in orthopedic patients during thromboprophylaxis with rivaroxaban and enoxaparin: a prospective cohort study.
Oswald E; Velik-Salchner C; Innerhofer P; Tauber H; Auckenthaler T; Ulmer H; Streif W
Blood Coagul Fibrinolysis; 2015 Mar; 26(2):136-44. PubMed ID: 25396759
[TBL] [Abstract][Full Text] [Related]
9. Standard- versus intermediate-dose enoxaparin for anti-factor Xa guided thromboprophylaxis in critically ill patients with COVID-19.
Hamilton DO; Main-Ian A; Tebbutt J; Thrasher M; Waite A; Welters I
Thromb J; 2021 Nov; 19(1):87. PubMed ID: 34781984
[TBL] [Abstract][Full Text] [Related]
10. Factor Xa Inhibitors and Direct Thrombin Inhibitors Versus Low-Molecular-Weight Heparin for Thromboprophylaxis After Total Hip or Total Knee Arthroplasty: A Systematic Review and Meta-Analysis.
Sun G; Wu J; Wang Q; Liang Q; Jia J; Cheng K; Sun G; Wang Z
J Arthroplasty; 2019 Apr; 34(4):789-800.e6. PubMed ID: 30685261
[TBL] [Abstract][Full Text] [Related]
11. Adequate thromboprophylaxis in critically ill patients.
Levi M
Crit Care; 2010; 14(2):142. PubMed ID: 20423535
[TBL] [Abstract][Full Text] [Related]
12. Plasma anti-FXa level as a surrogate marker of the adequacy of thromboprophylaxis in critically ill patients: A systematic review.
Vahtera A; Vaara S; Pettilä V; Kuitunen A
Thromb Res; 2016 Mar; 139():10-6. PubMed ID: 26916290
[TBL] [Abstract][Full Text] [Related]
13. Lobectomy and postoperative thromboprophylaxis with enoxaparin improve blood hypercoagulability in patients with localized primary lung adenocarcinoma.
Papageorgiou C; Vandreden P; Marret E; Bonnet F; Robert F; Spyropoulos A; Galea V; Elalamy I; Hatmi M; Gerotziafas GT
Thromb Res; 2013 Nov; 132(5):584-91. PubMed ID: 24094602
[TBL] [Abstract][Full Text] [Related]
14. Development of a dosage strategy in patients receiving enoxaparin by continuous intravenous infusion using modelling and simulation.
Feng Y; Green B; Duffull SB; Kane-Gill SL; Bobek MB; Bies RR
Br J Clin Pharmacol; 2006 Aug; 62(2):165-76. PubMed ID: 16842391
[TBL] [Abstract][Full Text] [Related]
15. Association of Anti-Factor Xa-Guided Dosing of Enoxaparin With Venous Thromboembolism After Trauma.
Karcutskie CA; Dharmaraja A; Patel J; Eidelson SA; Padiadpu AB; Martin AG; Lama G; Lineen EB; Namias N; Schulman CI; Proctor KG
JAMA Surg; 2018 Feb; 153(2):144-149. PubMed ID: 29071333
[TBL] [Abstract][Full Text] [Related]
16. Venous Thromboembolism Prophylaxis: A Narrative Review With a Focus on the High-Risk Critically Ill Patient.
Lewis TC; Cortes J; Altshuler D; Papadopoulos J
J Intensive Care Med; 2019; 34(11-12):877-888. PubMed ID: 30165770
[TBL] [Abstract][Full Text] [Related]
17. Plasma levels of enoxaparin oligosaccharides, antifactor-Xa and thrombin generation in patients undergoing haemodialysis.
Batt TJ; Lincz LF; Prasad R; Patel RP; Shastri M; Lioufas N; Smith AG; Jose MD
Blood Coagul Fibrinolysis; 2020 Mar; 31(2):152-159. PubMed ID: 31990754
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic profiles of intravenous versus subcutaneous administration of low molecular weight heparin for thromboprophylaxis in critically ill patients: A randomized controlled trial.
De Schryver N; Serck N; Eeckhoudt S; Laterre PF; Wittebole X; Gérard L
J Crit Care; 2022 Aug; 70():154029. PubMed ID: 35381407
[TBL] [Abstract][Full Text] [Related]
19. Comparison of enoxaparin and unfractionated heparin on thrombin generation in acute coronary syndromes without ST-segment elevation.
Salvioni A; Casilli F; Assanelli E; Grazi M; Marenzi G; Guazzi MD
Thromb Haemost; 2001 Oct; 86(4):991-4. PubMed ID: 11686357
[TBL] [Abstract][Full Text] [Related]
20. Thromboprophylaxis following caesarean section--a comparison of the antithrombotic properties of three low molecular weight heparins--dalteparin, enoxaparin and tinzaparin.
Ellison J; Thomson AJ; Conkie JA; McCall F; Walker D; Greer A
Thromb Haemost; 2001 Dec; 86(6):1374-8. PubMed ID: 11776302
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
